Why Pacira BioSciences, Inc. is positioning EXPAREL as a cost-saving tool in Medicare surgery
Find out how Pacira BioSciences, Inc.’s EXPAREL data could reduce opioid use and surgical costs in Medicare patients.
Pharma & Biotech
Features & Analysis
Is direct-to-patient pharma becoming the industry’s answer to drug pricing pressure?
Bristol Myers Squibb and Pfizer have brought Eliquis, the oral anticoagulant apixaban, into a new direct access channel through Mark Cuban Cost Plus Drug Company, making the medicine available to cash-paying patients in the United States from April 27, 2026. The move places one of the country’s most widely prescribed branded blood thinners inside a
Features & Analysis
Why Merck’s Terns acquisition puts chronic myeloid leukemia back in the oncology dealmaking spotlight
Merck needs more than Keytruda. TERN-701 could make chronic myeloid leukemia a sharper test of its next oncology strategy.
Pharma & Biotech
Why the Veradermics hair loss trial is bigger than another aesthetics readout
Hair loss drugs are old, demand is huge, and Veradermics now faces the data test that could reset oral minoxidil’s commercial future.
Pharma & Biotech
Can Ascletis Pharma challenge injectable GLP-1 leaders with oral ASC30?
Oral GLP-1s promise convenience, but proof is still clinical. Ascletis’ ASC30 diabetes trial could test whether hype can meet HbA1c data.
Pharma & Biotech
Why Sun Pharma’s $11.75bn Organon acquisition could reshape specialty pharma
Sun Pharma gets global scale with Organon. The harder test is whether women’s health, biosimilars, and debt discipline can move together.
Medical Devices & Diagnostics
Why Pulse Biosciences’ 12-month nsPFA data matters in a PFA market dominated by Farapulse and Affera
Boston Scientific owns the PFA market. Pulse Biosciences just posted 90% one-year AF freedom. Is nanosecond PFA a real disruption or an acquisition target?
Medical Devices & Diagnostics
Adagio Medical reports pivotal FULCRUM-VT results as FDA pathway sharpens for vCLAS ablation system
VT ablation remains difficult. Adagio Medical’s pivotal vCLAS data now shifts the question from feasibility to FDA and clinical adoption.
Medical Devices & Diagnostics
Is Abbott building the next integrated platform for complex heart rhythm treatment?
Abbott has PFA momentum, but rhythm care is becoming a platform battle. Can clinical data turn into durable adoption?
Pharma & Biotech
Can Brii Bio’s HBV rebound data move functional cure closer to clinical reality?
HBV cure hopes depend on durability, not just antigen loss. Brii Bio’s APASL data shifts attention to post-treatment control.